The retinoblastoma protein inhibits cancer by controlling cell division. Now, researchers have shown that it also binds to and inhibits genes necessary for pluripotency — a defining characteristic of stem cells.
November 13, 2014 - By Krista Conger
A protein that plays a critical role in preventing the development of many types of human cancers has been shown also to inhibit a vital stem cell property called pluripotency, according to a study by researchers at the Stanford University School of Medicine.
Blocking expression of the protein, called retinoblastoma, in mouse cells allowed the researchers to more easily transform them into what are known as induced pluripotent stem cells, or iPS cells. Pluripotent is a term used to describe a cell that is similar to an embryonic stem cell and can become any tissue in the body.
The study provides a direct and unexpected molecular link between cancer and stem cell science through retinoblastoma, or Rb, one of the best known of a class of proteins called tumor suppressors. Although Rb has long been known to control the rate of cell division, the researchers found that it also directly binds and inhibits the expression of genes involved in pluripotency.
“We were very surprised to see that retinoblastoma directly connects control of the cell cycle with pluripotency,” said Julien Sage, PhD, associate professor of pediatrics and of genetics. “This is a completely new idea as to how retinoblastoma functions. It physically prevents the reacquisition of stem cellness and pluripotency by inhibiting gene expression.”
Marius Wernig, MD, associate professor of pathology, said, “The loss of Rb appears to directly change a cell’s identity. Without the protein, the cell is much more developmentally fluid and is easier to reprogram into an iPS cell.”
Wernig and Sage, both members of the Stanford Cancer Institute, share senior authorship of the study, published online Nov. 13 in Cell Stem Cell. Postdoctoral scholar Michael Kareta, PhD, is the lead author.
Pluripotent stem cells are able to become any tissue in the body. In 2006, researchers in Shinya Yamanaka’s laboratory in Kyoto University found that it’s possible to push a fully specialized adult cell, such as a skin cell, backward along the developmental pathway to assume a pluripotent state. They did so by adding four proteins — Sox2, Oct4, cMyc and Klf4 — that are normally found in cells only very early in embryonic development. The resulting cells were called induced pluripotent stem cells.
Rb was first identified as a tumor suppressor because of its role in a rare but rapidly developing childhood cancer of the retina. It has since been shown to be missing or functionally inactive in nearly all human cancers. Intact Rb prevents cancer by acting as a natural brake on the cell cycle, the process by which cells divide to make daughter cells. Loss of Rb allows a cell to divide more quickly and potentially accumulate more cancer-causing mutations. However, the new research shows that Rb’s effect on pluripotency is independent of its role in cell cycle control.
Cancerous cells often appear less mature than their noncancerous peers. They persist in dividing in the face of external cues that curb the proliferation of normal cells, and they often seem to regress developmentally, assuming the form and mimicking the behavior of their more developmentally flexible ancestors. A similar cascade of events occurs when researchers create iPS cells from specialized adult cells.
“The process of creating iPS cells from fully differentiated, or specialized, cells is in many ways very similar to what happens when a cell becomes cancerous,” said Sage, who holds the Harriet and Mary Zelencik Endowed Professorship in Pediatrics. “We wondered if we could learn more about both processes by investigating whether the loss of Rb affects reprogramming efficiency.”
Previous studies in other laboratories have suggested that Rb may also be involved in promoting cellular differentiation — a cell’s developmental progression toward a more specialized state.
Link between Rb and pluripotency
The researchers found that embryonic mouse cells unable to express functional Rb were much more efficiently and quickly converted to iPS cells than were cells in which Rb was present. Conversely, cells with higher-than-normal levels of the Rb protein were more difficult to reprogram into iPS cells. When the researchers compared the rate of division of the control cells with those in which Rb expression was lost, they found no significant differences.
“It didn’t change the cell proliferation rates at all,” said Wernig. “This indicated that Rb’s mechanism of action on reprogramming was something completely different than what we had expected.”
Further investigation showed that Rb directly binds to many genes involved in the acquisition of pluripotency, including those encoding two of the proteins often used by researchers to create iPS cells: Sox2 and Oct4. Loss of Rb increased the expression of the proteins, thereby affecting a large “pluripotency network.”
“We saw a global effect on a network of genes involved in pluripotency,” said Sage. The net effect, according to the researchers, is an overall reduction in the natural barrier that exists to prevent specialized adult cells from dedifferentiating — that is, spontaneously becoming pluripotent, an occurrence that could easily wreak havoc on a multicellular organism that depends on an orderly arrangement of tissues.
We saw a global effect on a network of genes involved in pluripotency.
The researchers also showed that Rb’s effect on the pluripotency network is an important driver of cancer in a mouse model. Animals in which Rb expression is blocked typically develop pituitary tumors within a few months. However, the researchers found the cancers didn’t occur when Sox2 was also removed.
“It’s clear that Sox2 expression is also required for the development of cancers in the animals,” said Wernig. “This implies that Rb’s effect on Sox2 expression is critical for cancer development.”
The researchers plan to continue their investigations into the relationship between Rb and pluripotency. In particular, Wernig is interested in learning whether Rb expression plays a role in a phenomenon he discovered called direct conversion, in which one cell type, such as a skin cell, can be directly converted into another, such as a neuron, without first entering a pluripotent state.
Other Stanford co-authors are former postdoctoral scholar Laura Gorges, PhD; research assistants Sana Hafeez, Anne-Flore Zmoos and Megan O’Brien; postdoctoral scholars Samuele Marro, PhD, Berenice Benayoun, PhD, and Luis Batista, PhD; graduate students Yi-Han Ng, Damek Spacek and Cheen Euong Ang; data analyst Dedeepya Vaka; Steven Artandi, MD, PhD, professor of medicine and of biochemistry; and Anne Brunet, PhD, associate professor of genetics.
The research was supported by the National Cancer Institute (grant CA09151), Spectrum Child Health, the Lucile Packard Foundation for Children’s Health, the California Institute for Regenerative Medicine and the New York Stem Cell Foundation.
Information about Stanford’s pathology, genetics and pediatrics departments, which also supported the work, is available at http://pediatrics.stanford.edu, http://genetics.stanford.edu, and http://pathology.stanford.edu.
About Stanford Medicine
Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.